Catalent Partnering with Multiple Customers on COVID-Related Vaccines and TherapiesIncluding Johnson & Johnson and Arcturus Therapeutics Learn More CATALENT HAS ACQUIRED MASTHERCELLEnhancing capabilities in cell and gene therapy development and manufacturing to create a comprehensive solution for advanced biotherapeutics Learn More Your one comprehensive BIOLOGICS partnerHelping simplify your process and deliver better therapies to your patients faster Play Video Your Expert Partner in Gene TherapyIndustry-leading expertise in adeno-associated viral vector (AAV) development and manufacturing Learn More Introducing OneBio™ SuiteAccelerating timelines through integrated biologics development, manufacturing & supply Learn More Catalent Partnering with Multiple Customers on COVID-Related Vaccines and TherapiesIncluding Johnson & Johnson and Arcturus Therapeutics Learn More CATALENT HAS ACQUIRED MASTHERCELLEnhancing capabilities in cell and gene therapy development and manufacturing to create a comprehensive solution for advanced biotherapeutics Learn More Your one comprehensive BIOLOGICS partnerHelping simplify your process and deliver better therapies to your patients faster Play Video Your Expert Partner in Gene TherapyIndustry-leading expertise in adeno-associated viral vector (AAV) development and manufacturing Learn More Introducing OneBio™ SuiteReducing timelines, risk & complexity through integrated biologics development, manufacturing & supply Learn More How can we work together BiologicsDevelopment Gene Therapy Specialty Technologies Latest News Triphase Accelerator and Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Non-Hodgkin’s Lymphoma CATALENT RESPONDS TO THE GLOBAL COVID-19 OUTBREAK We are taking decisive action to minimize the impact of the COVID-19 pandemic on our employees, partners, customers, and their patients. LEARN MORE Gene Therapy With experience across more than 60 gene therapy programs and leading expertise in AAV Vectors, Catalent’s Gene Therapy team will provide you with full life cycle support of your life-saving therapeutic. Cell Therapy With our advanced technologies and expertise in both autologous and allogeneic development and manufacturing, Catalent is your full-service partner for CAR-T immunotherapies and beyond. STRATEGIES TO ACHIEVE SUCCESSFUL COMMERCIAL APPROVAL & LAUNCH Experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the successful launch and approval of a biologic. Biologics Network Our network of biologics sites provides an integrated approach to get medicines to your patients faster anywhere in the world. SEE ALL LOCATIONS Join Our Team Catalent is growing in Biologics and is making significant investments in people in this area. Explore global career opportunities with our Biologics team. NEWS Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual Triphase Accelerator and Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Non-Hodgkin’s Lymphoma Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine Catalent Announces Next Generation of Cell & Gene Therapy Leadership VIEW ALL NEWS EVENTS ASCO Explained Cell Therapy Presentation at ISCT 2020 Webinar: The Outlook for Cancer Gene Therapies BIO Digital VIEW ALL EVENTS EXPERT CONTENT Advances in Analytical Technology for Biopharmaceuticals Prefilled Syringes & Parental Manufacturing Accelerating Method Transfer: Effective Automation Of Biological Assays VIEW ALL ARTICLES
